SAS India

News

Analyst Viewpoints
Awards
e-Newsletters
Features
SAS in the News
sascom online Magazine
Subscribe sascom

SAS TARGETS DRUG DEVELOPMENT MARKET

SAS, a significant player in the Business Intelligence space, has announced the launch of the SAS Drug Development 3.0 tool with an aim to tap an estimated $100-million clinical research market in India. The application provides a centralised repository that allows life science firms to analyse clinical research for regulatory submission and meeting federal regulations such as 21 CFR Part 11.

According to Sudipta Sen, Managing Director and CEO, SAS India, “Pharmaceutical companies in India are gearing to find innovative ways to effectively manage, analyse and explore massive amounts of complex data and still minimise their time to market.” Sen adds that as the drug development tool allows users to access research and clinical trials data scattered in silos across different departments, users can integrate data quickly in a regulatory-compliant manner.